VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME
Click Here to Manage Email Alerts
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Samuel A. Minaker, MD, discusses the 0.19 mg fluocinolone acetonide implant for diabetic macular edema.
According to Minaker, 70% of patients in the PALADIN real-world safety study did not require any intervention after treatment, and the need for surgery was rare. The study also looked at the variability of central subfield thickness and its effect on vision outcomes.
“When we looked at the need for treatment in these quartiles, these patients’ visual gains were not driven by additional supplemental treatment by VEGF, but it was driven by the durability of this implant,” Minaker said. “This is a great therapy that you can offer to your patients as a secondary therapy for diabetic macular edema.”
Collapse
Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Read more about
Click Here to Manage Email Alerts